(Q51693639)

9 April 2018

title

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. (English)

1 reference

9 April 2018

1 reference

9 April 2018

Stephanie R. McKeown

object named as

Stephanie R McKeown

1 reference

9 April 2018

Laurence Patterson

object named as

Laurence H Patterson

1 reference

9 April 2018

author name string

Helen O McCarthy

1 reference

9 April 2018

Anita Yakkundi

1 reference

9 April 2018

Verna McErlane

1 reference

9 April 2018

Ciara M Hughes

1 reference

9 April 2018

Gillian Keilty

1 reference

9 April 2018

Margaret Murray

1 reference

9 April 2018

David G Hirst

1 reference

9 April 2018

publication date

1 January 2003

1 reference

9 April 2018

published in

Cancer Gene Therapy

1 reference

9 April 2018

volume

1 reference

9 April 2018

issue

1 reference

9 April 2018

page(s)

40-48

1 reference

9 April 2018

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Gene therapy - promises, problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

The macrophage - a novel system to deliver gene therapy to pathological hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

High Levels of Recombinant CYP3A4 Expression in Chinese Hamster Ovary Cells Are Modulated by Coexpressed Human P450 Reductase and Hemin Supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

A simple technique for quantitation of low levels of DNA damage in individual cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

The single cell gel electrophoresis assay (comet assay): A European review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

inferred from DOI database lookup

7 January 2021

based on heuristic

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

inferred from DOI database lookup

7 January 2021

based on heuristic

High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700522

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.CGT.7700522

1 reference

9 April 2018

1 reference

9 April 2018